Greenwich LifeSciences, Inc.

GLSI

$15.63

-0.70%

N/A-$0.11

Healthcare

Biotechnology

NASDAQ

Active Trading

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast ...

Recent News of GLSI

Market Watch8/27/2026Neutral

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

GlobeNewsWire8/10/2026Neutral

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.

GlobeNewsWire7/22/2026Neutral

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.

GlobeNewsWire7/20/2026Neutral

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01.

GlobeNewsWire7/16/2026Neutral

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.

Market Watch•8/27/2026

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

Neutral

General

GLSI: Neutral

GlobeNewsWire•8/10/2026

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Neutral

General

GLSI: Neutral

GlobeNewsWire•7/22/2026

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

Neutral

General

GLSI: Neutral

GlobeNewsWire•7/20/2026

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Neutral

General

GLSI: Neutral

GlobeNewsWire•7/16/2026

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Neutral

General

GLSI: Neutral

Seeking Alpha•7/16/2026

Greenwich LifeSciences The Overlooked Need

Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer.

Neutral

General

GLSI: Neutral

GlobeNewsWire•7/9/2026

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.

Neutral

General

GLSI: Neutral

GlobeNewsWire•6/1/2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026.

Neutral

General

GLSI: Neutral

Globe News Wire•6/1/2026

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

Neutral

General

GLSI: Neutral

GlobeNewsWire•6/1/2026

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

Neutral

General

GLSI: Neutral

Supply Chain of GLSI

RELATIONS

Upstream

PolyPeptide Group AG (Polypeptide Laboratories, San Diego)SIX:PPGNPartner Therapeutics, Inc. (PTx)Unnamed Fill-Finish CDMO PartnerUnnamed Third-Party Raw Material SuppliersSanofi S.A.NASDAQ:SNYUnnamed Peptide Synthesis Raw Material Suppliers

Downstream

US Oncology Research / Sarah Cannon Research Institute (SCRI)NYSE:MCKTRIO US (Translational Research in Oncology US)GEICAM (Spanish Breast Cancer Research Group)GIM (Gruppo Italiano Mammella)UnicancerGBG (German Breast Group)City of Hope National Medical CenterRedChip Companies, Inc.

Proxies

PolyPeptide Group AGSIX:PPGNBachem Holding AGSIX:BANBImmunityBio, Inc.NASDAQ:IBRX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer